ENIGMA is an international consortium of investigators focused on determining the clinical significance of sequence variants in BRCA1, BRCA2 and other known or suspected breast cancer genes, to provide this expert opinion to global database and classification initiatives, and to explore optimal avenues of communication of such information at the provider and patient level.
Co-ordination of ENIGMA has received funding from:
The National Institutes of Health Recovery Act supplement award (CA116167Z) [2010-2012]
A Breast Cancer Specialized Program of Research Excellence (SPORE) at the Mayo Clinic (P50 CA116201) [2009-Present]
Use of the ENIGMA website and database, and associated interpretation relating to gene variant pathogenicity, is subject to User discretion and responsibility. The information provided is for research purposes, and is not a substitute for professional risk assessment.
All clinical decisions regarding patient care and treatment should be carried out in conjunction with a health care professional experienced in cancer genetic risk assessment.
Listed information on gene variant classification is subject to change as further information becomes available, and there is no warranty, express or implied, as to its accuracy, completeness, or fitness for a particular purpose.
The ENIGMA Steering Committee does not accept any responsibility or liability with regard to the reliance on, and/or use of, data and information contained herein.